(Q43791685)

English

Clinical-benefit response in advanced non-small-cell lung cancer: A multicentre prospective randomised phase III study of single agent gemcitabine versus cisplatin-vindesine

scientific article published in September 2001

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Clinical-benefit response in advanced non-small-cell lung cancer: A multicentre prospective randomised phase III study of single agent gemcitabine versus cisplatin-vindesine (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

1 reference

based on heuristic

inferred from title

author name string

J F Vansteenkiste

1

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

J E Vandebroek

2

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

K L Nackaerts

3

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

P Weynants

4

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Y J Valcke

5

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

D A Verresen

6

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

R C Devogelaere

7

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

S A Marien

8

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Y P Humblet

9

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

N L Dams

10

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Leuven Lung Cancer Group

11

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

publication date

1 September 2001

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

1221-1230

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Polychemotherapy in advanced non small cell lung cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012208711013

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough?

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012208711013

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012208711013

7 January 2021

based on heuristic

inferred from DOI database lookup

Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012208711013

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012208711013

7 January 2021

based on heuristic

inferred from DOI database lookup

Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012208711013

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a phase II randomized study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012208711013

7 January 2021

based on heuristic

inferred from DOI database lookup

Single-agent gemcitabine versus cisplatin-etoposide: early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012208711013

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized study of cisplatin versus cisplatin plus vindesine for non-small cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012208711013

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized trial in inoperable non-small-cell lung cancer: vindesine and cisplatin versus mitomycin, vindesine, and cisplatin versus etoposide and cisplatin alternating with vindesine and mitomycin

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012208711013

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomised trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012208711013

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized comparison of two combination regimens versus minimal chemotherapy in nonsmall-cell lung cancer: a Southeastern Cancer Study Group Trial

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012208711013

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012208711013

7 January 2021

based on heuristic

inferred from DOI database lookup

Improving the quality of reporting of randomized controlled trials. The CONSORT statement

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012208711013

7 January 2021

based on heuristic

inferred from DOI database lookup

Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012208711013

7 January 2021

based on heuristic

inferred from DOI database lookup

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012208711013

7 January 2021

based on heuristic

inferred from DOI database lookup

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012208711013

7 January 2021

based on heuristic

inferred from DOI database lookup

Quality of life assessment in individuals with lung cancer: testing the Lung Cancer Symptom Scale (LCSS).

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012208711013

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012208711013

7 January 2021

based on heuristic

inferred from DOI database lookup

Hemolytic-uremic syndrome caused by gemcitabine

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012208711013

7 January 2021

based on heuristic

inferred from DOI database lookup

A fatal case of cholestatic liver failure probably related to gemcitabine.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012208711013

7 January 2021

based on heuristic

inferred from DOI database lookup

Measurable or assessable disease in lung cancer trials: does it matter?

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012208711013

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012208711013

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine-induced hemolytic uremic syndrome: a case report

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012208711013

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012208711013

7 January 2021

based on heuristic

inferred from DOI database lookup

Fatal pulmonary failure complicating high-dose cytosine arabinoside therapy in acute leukemia

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012208711013

7 January 2021

based on heuristic

inferred from DOI database lookup

Fatal pulmonary toxicity resulting from treatment with gemcitabine

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012208711013

7 January 2021

based on heuristic

inferred from DOI database lookup

Are platinum compounds mandatory in the treatment of metastatic non-small cell lung cancer?

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012208711013

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer--a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012208711013

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1023/A:1012208711013

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43791685&oldid=2103366374"